Evidence map›Paper›PMID 40799826›Full record

ArticleFrontiers in pharmacology2025

HDL attenuates Ang II-AT1R-EGFR signaling and reverses vascular remodeling in spontaneously hypertensive rats.

Aishah Al-Jarallah, Samah Kalakh, Saghir Akhtar, Mariam H M Yousif

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Aishah Al-JarallahDepartment of Biochemistry, College of Medicine, Kuwait University, Kuwait City, Kuwait.
Samah KalakhDepartment of Biochemistry, College of Medicine, Kuwait University, Kuwait City, Kuwait.
Saghir AkhtarCollege of Medicine, QU Health, Qatar University, Doha, Qatar.
Mariam H M YousifDepartment of Pharmacology and Toxicology, College of Medicine, Kuwait University, Kuwait City, Kuwait.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Angiotensin II (Ang II) signaling via angiotensin II type 1 receptor (AT1R) and transactivation of epidermal growth factor receptor (EGFR) enhances vascular smooth muscle cell (VSMC) proliferation and contributes to vascular remodeling evident in spontaneously hypertensive rats (SHR) aorta. Although high-density lipoprotein (HDL) has been shown to lower blood pressure in SHR, the underlying mechanism(s) remain incompletely understood. We propose that HDL attenuates Ang II-AT1R-EGFR signaling and reverses vascular remodeling in SHR. Methods: Wistar Kyoto rats (WKY) and SHR were treated with HDL for 1 week. Vascular remodeling was histologically examined. VSMC proliferation and the expression levels of AT1R, EGFR, extracellular signal regulated kinases 1/2 (ERK1/2), scavenger receptor class B type-I (SR-BI) and its adaptor protein PDZK1 were examined by immunofluorescence. VSMC proliferation was further examined Results: HDL treatment reduced blood pressure, increased the production of nitric oxide, increased aortic lumen diameter, reduced media thickness to lumen diameter ratio, decreased collagen contents in SHR. Furthermore, HDL treatment decreased the number of proliferating VSMCs and α-smooth muscle actin, reduced the expression of AT1R and EGFR and increased the expression of SR-BI adaptor protein, PDZK1, in SHR aortas. In isolated VSMCs, HDL attenuated Ang II-induced proliferation by reducing AT1R expression and decreasing Ang II-induced transactivation of EGFR. HDL effects were SR-BI dependent and were mimicked by different HDL subpopulations, reconstituted HDL, and lipid free apolipoprotein A-I. Conclusion: HDL attenuates Ang II-AT1R-EGFR signaling, reduces VSMC proliferation, and reverses vascular remodeling in SHR. HDL modulation of vascular remodeling could be one mechanism by which HDL reduces blood pressure in SHR.

Indexed as

angiotensin IIHDLproliferationSR-BIvascular remodeling

Identifiers

PMID40799826
PMCPMC12339555

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.